Neumedicines Inc.

Neumedicines Inc. develops HemaMax™, a proprietary recombinant human interleukin‑12 immunotherapeutic designed to stimulate hematopoiesis and potent immune responses. The company has demonstrated compelling preclinical results in animal models and clinical efficacy in Phase II trials for CTCL when combined with radiation therapy—showing a significant increase in duration of response compared to radiation alone. HemaMax also shows promise as a radiomitigating agent post-radiation exposure without supportive care. The product’s unique glycosylation profile improves pharmacokinetics/dynamics while minimizing toxicity historically associated with IL‑12 therapies.